Evidence map›Paper›PMID 36009233›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Antioxidant, Anti-Proliferative Activity and Chemical Fingerprinting of

Mourad A M Aboul-Soud, Hanane Ennaji, Ashok Kumar, Mohammad A Alfhili, Ahmed Bari, Maqusood Ahamed, Mohamed Chebaibi, Mohammed Bourhia, Farid Khallouki, Khalid M Alghamdi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Frontiers in nutrition · 2026
    Article
  5. Phytochemical Profiling and Molecular Insights ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Phytochemical Analysis ofLife (Basel, Switzerland) · 2024
    Article
  10. Article
  11. Phenolic Composition ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  12. Molecular Actions ofAnti-cancer agents in medicinal chemistry · 2024
    Article
  13. Frontiers in chemistry · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Cardioprotective Effect ofMolecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Mourad A M Aboul-SoudChair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia.ORCID 0000-0001-9395-0563
Hanane EnnajiLaboratory of Chemistry-Biochemistry, Environment, Nutrition and Health, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca B.P. 5696, Morocco.
Ashok KumarVitiligo Research Chair, Department of Dermatology, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia.
Mohammad A AlfhiliChair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia.ORCID 0000-0002-3095-9154
Ahmed BariDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-9447-2361
Maqusood AhamedKing Abdullah Institute for Nanotechnology, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-6025-1950
Mohamed ChebaibiBiomedical and Translational Research Laboratory, Faculty of Medicine and Pharmacy, University of Sidi Mohamed Ben Abdellah, BP 1893, Km 22, Road of Sidi Harazem, Fez B.F. 1893, Morocco.ORCID 0000-0001-6614-9594
Mohammed BourhiaHigher Institute of Nursing Professions and Technical Health, Laayoune 70000, Morocco.ORCID 0000-0003-3707-8461
Farid KhalloukiBiology Department, FTSE, Moulay Ismail University of Meknes, BP 609, Errachidia 52000, Morocco.
Khalid M AlghamdiVitiligo Research Chair, Department of Dermatology, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia.
John P GiesyToxicology Centre, University of Saskatchewan, Saskatoon, SK S7N 5B3, Canada.
King Saud University · SAInstituts Supérieurs des Professions Infirmières et Techniques de Santé · MASidi Mohamed Ben Abdellah University · MAUniversité Moulay Ismail de Meknes · MAUniversity of Hassan II Casablanca · MAUniversity of Saskatchewan · CA

Funding

King Saud University Vice Deanship of Research Chairs
6 · The paper itself

Abstract

Centaurea calcitrapa has been intensively utilized in ethnomedicinal practices as a natural therapeutic recipe to cure various ailments. The current study aimed to chemically characterize ethanolic extract of C. calcitrapa (EECC) aerial parts (leaves and shoots) by use of gas chromatography-mass spectrometry analyses (GC-MS) and investigate its antioxidant and in vitro anticancer activities, elucidating the underlying molecular mechanism by use of flow cytometry-based fluorescence-activated cell sorting (FACS) and conducting in silico assessment of binding inhibitory activities of EECC major compounds docked to caspase-3. CG-MS profiling of EECC identified a total of 26 major flavonoids and polyphenolic compounds. DPPH and ABTS assays revealed that EECC exhibits potent antioxidant activity comparable to standard reducing agents. Results of the proliferation assay revealed that EECC exhibit potent, dose-dependent cytotoxic activities against triple-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cell models, with IC50 values of 1.3 × 102 and 8.7 × 101 µg/mL, respectively. The observed cytotoxic effect was specific to studied cancer cells since EECC exhibited minimal (~<10%) cytotoxicity against MCF-12, a normal breast cell line. FACS analysis employing annexin V-FITC/propidium iodide double labeling demonstrated that the observed anti-proliferative activity against MCF-7 and MDA-MB-231 was mediated via apoptotic as well as necrotic signaling transduction processes. The increase in fluorescence intensity associated with DCFH oxidation to DCF, as reported by FACS, indicated that apoptosis is caused by generation of ROS. The use of caspase-3-specific fluorogenic substrate revealed a dose-dependent elevation in caspase-3 substrate-cleavage activity, which further supports EECC-mediated apoptosis in MCF-7 cells. The major EECC compounds were examined for their inhibitory activity against caspase-3 receptor (1HD2) using molecular docking. Three compounds exhibited the highest glide score energy of −5.156, −4.691 and −4.551 kcal/mol, respectively. Phenol, 2,6-dimethoxy established strong binding in caspase-3 receptor of hydrogenic type, with residue ARG 207 and of PI-PI stacking type with residue HIS 121. By contract, hexadecenoic acid showed 3 H-bond with the following residues: ASN 615, ASN 616a and THR 646. Taken together, the current findings reveal that EECC exhibits significant and specific cytotoxicity against breast cancer cells mediated by the generation of ROS and culminating into necrosis and apoptosis. Further investigations of the phytoconstituents-rich C. calcitrapa are therefore warranted against breast as well as other human cancer cell models.

Indexed as

antioxidant potentialapoptosisbreast cancercaspase-3CG-MS profilingpurple star thistle

Identifiers

PMID36009233
PMCPMC9405406
OpenAlexW4289705011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.